Roivant Sciences (ROIV) Stock Forecast, Price Target & Predictions
ROIV Stock Forecast
Roivant Sciences stock forecast is as follows: an average price target of $16.21 (represents a 37.14% upside from ROIV’s last price of $11.82) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.
ROIV Price Target
The average price target for Roivant Sciences (ROIV) is $16.21 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $20.00 to $12.50. This represents a potential 37.14% upside from ROIV's last price of $11.82.
ROIV Analyst Ratings
According to 10 Wall Street analysts, Roivant Sciences's rating consensus is 'Buy'. The analyst rating breakdown for ROIV stock is 0 'Strong Buy' (0.00%), 9 'Buy' (90.00%), 1 'Hold' (10.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Roivant Sciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 21, 2024 | David Risinger | Leerink Partners | $17.00 | $11.92 | 42.62% | 43.82% |
| Sep 19, 2024 | Corinne Jenkins | Goldman Sachs | $17.00 | $12.05 | 41.02% | 43.82% |
| Sep 11, 2024 | Chi Fong | Bank of America Securities | $12.50 | $12.46 | 0.36% | 5.75% |
| May 31, 2024 | Allison Bratzel | Piper Sandler | $20.00 | $10.39 | 92.49% | 69.20% |
| Apr 03, 2024 | Douglas Tsao | H.C. Wainwright | $18.00 | $10.92 | 64.84% | 52.28% |
| Apr 03, 2024 | Neena Bitritto-Garg | Deutsche Bank | $15.00 | $10.92 | 37.36% | 26.90% |
| Apr 02, 2024 | Corinne Jenkins | Goldman Sachs | $18.00 | $10.92 | 64.84% | 52.28% |
| Mar 13, 2024 | Corinne Jenkins | Goldman Sachs | $16.00 | $10.62 | 50.66% | 35.36% |
| Jan 05, 2023 | - | Citigroup | $14.00 | $7.56 | 85.19% | 18.44% |
| Dec 19, 2022 | - | Leerink Partners | $10.00 | $7.32 | 36.61% | -15.40% |
The latest Roivant Sciences stock forecast, released on Oct 21, 2024 by David Risinger from Leerink Partners, set a price target of $17.00, which represents a 42.62% increase from the stock price at the time of the forecast ($11.92), and a 43.82% increase from ROIV last price ($11.82).
Roivant Sciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 3 | 8 |
| Avg Price Target | - | $15.50 | $16.69 |
| Last Closing Price | $11.82 | $11.82 | $11.82 |
| Upside/Downside | -100.00% | 31.13% | 41.20% |
In the current month, the average price target of Roivant Sciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Roivant Sciences's last price of $11.82. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 21, 2024 | Leerink Partners | Outperform | Outperform | Hold |
| Sep 19, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Sep 11, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Sep 11, 2024 | Piper Sandler | Buy | Buy | Hold |
| Sep 11, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 11, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 11, 2024 | Bank of America Securities | Neutral | Neutral | Hold |
| Jul 10, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 31, 2024 | Goldman Sachs | Underperform | Underperform | Hold |
| May 31, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Roivant Sciences's last stock rating was published by Leerink Partners on Oct 21, 2024. The company gave ROIV a "Outperform" rating, the same as its previous rate.
Roivant Sciences Financial Forecast
Roivant Sciences Revenue Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $37.14M | $18.42M | - | $27.38M | $17.05M | $13.99M |
| Avg Forecast | $6.00M | $6.00M | $6.00M | $6.00M | $3.90M | $3.90M | $4.11M | $30.66M | $23.95M | $8.14M | $45.92M | $30.72M | $31.01M | $31.77M | $27.11M | $24.49M | $18.17M | $14.78M | $7.22M |
| High Forecast | $15.05M | $15.05M | $6.00M | $6.00M | $9.78M | $9.78M | $10.30M | $76.93M | $64.35M | $15.71M | $115.21M | $30.72M | $31.05M | $38.53M | $47.69M | $61.43M | $45.58M | $37.07M | $7.22M |
| Low Forecast | $804.68K | $804.68K | $6.00M | $6.00M | $523.04K | $523.04K | $550.76K | $4.11M | $3.48M | $462.66K | $6.16M | $30.72M | $30.96M | $25.41M | $21.06M | $3.28M | $2.44M | $1.98M | $7.22M |
| # Analysts | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 3 | 3 | 6 | 9 | 6 | 4 | 3 | 7 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.17% | 0.68% | - | 1.51% | 1.15% | 1.94% |
Roivant Sciences's average Quarter revenue forecast for Mar 24 based on 3 analysts is $31.01M, with a low forecast of $30.96M, and a high forecast of $31.05M. ROIV's average Quarter revenue forecast represents a -16.51% decrease compared to the company's last Quarter revenue of $37.14M (Dec 23).
Roivant Sciences EBITDA Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 3 | 3 | 6 | 9 | 6 | 4 | 3 | 7 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-224.78M | $-276.45M | - | $-203.10M | $-221.04M | $-1.16B |
| Avg Forecast | $-3.60M | $-3.60M | $-3.60M | $-3.60M | $-2.34M | $-2.34M | $-2.46M | $-18.40M | $-14.37M | $-4.89M | $-27.55M | $-18.43M | $-18.60M | $-19.06M | $-16.26M | $-14.69M | $-10.90M | $-8.87M | $-4.33M |
| High Forecast | $-482.81K | $-482.81K | $-3.60M | $-3.60M | $-313.82K | $-313.82K | $-330.45K | $-2.47M | $-2.09M | $-277.60K | $-3.70M | $-18.43M | $-18.58M | $-15.24M | $-12.63M | $-1.97M | $-1.46M | $-1.19M | $-4.33M |
| Low Forecast | $-9.03M | $-9.03M | $-3.60M | $-3.60M | $-5.87M | $-5.87M | $-6.18M | $-46.16M | $-38.61M | $-9.42M | $-69.13M | $-18.43M | $-18.63M | $-23.12M | $-28.62M | $-36.86M | $-27.35M | $-22.24M | $-4.33M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.79% | 17.00% | - | 18.63% | 24.93% | 267.79% |
undefined analysts predict ROIV's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Roivant Sciences's previous annual EBITDA (undefined) of $NaN.
Roivant Sciences Net Income Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 3 | 3 | 6 | 9 | 6 | 4 | 3 | 7 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $5.10B | $-304.33M | - | $-175.42M | $-384.90M | $-225.64M |
| Avg Forecast | $-257.41M | $-250.06M | $-257.94M | $-250.12M | $-242.71M | $-205.93M | $-185.71M | $-150.77M | $-145.46M | $-165.89M | $-181.66M | $-178.96M | $-194.42M | $-227.26M | $-211.82M | $-208.38M | $-265.77M | $-290.13M | $-254.11M |
| High Forecast | $32.34M | $31.42M | $-257.94M | $-250.12M | $30.50M | $25.88M | $23.33M | $18.94M | $-138.53M | $-138.25M | $22.83M | $22.49M | $24.43M | $-176.76M | $-157.16M | $26.18M | $33.39M | $36.46M | $-254.11M |
| Low Forecast | $-762.33M | $-740.55M | $-257.94M | $-250.12M | $-718.77M | $-609.87M | $-549.97M | $-446.51M | $-152.39M | $-186.63M | $-537.99M | $-529.99M | $-575.78M | $-252.51M | $-232.31M | $-617.12M | $-787.07M | $-859.21M | $-254.11M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -22.42% | 1.44% | - | 0.66% | 1.33% | 0.89% |
Roivant Sciences's average Quarter net income forecast for Mar 24 is $-194.42M, with a range of $-575.78M to $24.43M. ROIV's average Quarter net income forecast represents a -103.82% decrease compared to the company's last Quarter net income of $5.10B (Dec 23).
Roivant Sciences SG&A Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 3 | 3 | 6 | 9 | 6 | 4 | 3 | 7 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $197.28M | $164.35M | - | $125.51M | $168.26M | $437.78M |
| Avg Forecast | $54.13M | $54.13M | $54.25M | $54.25M | $35.19M | $35.19M | $37.05M | $276.64M | $216.05M | $73.46M | $414.30M | $277.14M | $279.75M | $286.65M | $244.54M | $220.91M | $163.90M | $133.31M | $65.30M |
| High Forecast | $135.81M | $135.81M | $54.25M | $54.25M | $88.27M | $88.27M | $92.95M | $694.05M | $580.54M | $141.71M | $1.04B | $277.15M | $280.15M | $347.60M | $430.30M | $554.24M | $411.21M | $334.46M | $65.30M |
| Low Forecast | $7.26M | $7.26M | $54.25M | $54.25M | $4.72M | $4.72M | $4.97M | $37.10M | $31.38M | $4.17M | $55.56M | $277.14M | $279.34M | $229.22M | $189.98M | $29.63M | $21.98M | $17.88M | $65.30M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.69% | 0.67% | - | 0.77% | 1.26% | 6.70% |
Roivant Sciences's average Quarter SG&A projection for Mar 24 is $279.75M, based on 3 Wall Street analysts, with a range of $279.34M to $280.15M. The forecast indicates a 41.80% rise compared to ROIV last annual SG&A of $197.28M (Dec 23).
Roivant Sciences EPS Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 3 | 3 | 6 | 9 | 6 | 4 | 3 | 7 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $6.37 | $-0.40 | - | $-0.24 | $-0.54 | $-0.33 |
| Avg Forecast | $-0.35 | $-0.34 | $-0.33 | $-0.32 | $-0.33 | $-0.28 | $-0.25 | $-0.20 | $-0.20 | $-0.23 | $-0.25 | $-0.24 | $-0.26 | $-0.31 | $-0.29 | $-0.28 | $-0.36 | $-0.39 | $-0.33 |
| High Forecast | $0.04 | $0.04 | $-0.33 | $-0.32 | $0.04 | $0.04 | $0.03 | $0.03 | $-0.19 | $-0.19 | $0.03 | $0.03 | $0.03 | $-0.24 | $-0.21 | $0.04 | $0.05 | $0.05 | $-0.33 |
| Low Forecast | $-1.04 | $-1.01 | $-0.33 | $-0.32 | $-0.98 | $-0.83 | $-0.75 | $-0.61 | $-0.21 | $-0.25 | $-0.73 | $-0.72 | $-0.78 | $-0.34 | $-0.32 | $-0.84 | $-1.07 | $-1.17 | $-0.33 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -20.61% | 1.39% | - | 0.66% | 1.37% | 1.02% |
According to 3 Wall Street analysts, Roivant Sciences's projected average Quarter EPS for Mar 24 is $-0.26, with a low estimate of $-0.78 and a high estimate of $0.03. This represents a -104.15% decrease compared to ROIV previous annual EPS of $6.37 (Dec 23).
Roivant Sciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| INZY | Inozyme Pharma | $2.69 | $14.67 | 445.35% | Buy |
| PLRX | Pliant Therapeutics | $12.85 | $39.71 | 209.03% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.34 | $38.80 | 190.85% | Buy |
| LYRA | Lyra Therapeutics | $0.18 | $0.50 | 177.78% | Hold |
| PHAT | Phathom Pharmaceuticals | $9.45 | $25.83 | 173.33% | Buy |
| APLS | Apellis Pharmaceuticals | $27.75 | $74.50 | 168.47% | Buy |
| CGEM | Cullinan Oncology | $12.22 | $31.50 | 157.77% | Buy |
| SNDX | Syndax Pharmaceuticals | $15.60 | $34.30 | 119.87% | Buy |
| VRDN | Viridian Therapeutics | $19.62 | $37.92 | 93.27% | Buy |
| ASND | Ascendis Pharma | $122.64 | $190.21 | 55.10% | Buy |
| AKRO | Akero Therapeutics | $31.20 | $46.00 | 47.44% | Buy |
| ROIV | Roivant Sciences | $11.82 | $16.21 | 37.14% | Buy |
| BGNE | BeiGene | $194.56 | $255.80 | 31.48% | Buy |
| BPMC | Blueprint Medicines | $96.62 | $109.71 | 13.55% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $56.78 | $60.63 | 6.78% | Buy |
| KRYS | Krystal Biotech | $182.29 | $191.00 | 4.78% | Buy |
| RXDX | Prometheus Biosciences | $199.92 | $138.57 | -30.69% | Buy |